Compare TRAK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | IKT |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.5M | 201.3M |
| IPO Year | 1996 | 2020 |
| Metric | TRAK | IKT |
|---|---|---|
| Price | $8.72 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 115.5K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | 20.69 | ★ 67.51 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $47.17 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $8.11 | $1.33 |
| 52 Week High | $23.72 | $2.58 |
| Indicator | TRAK | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 57.80 |
| Support Level | $8.11 | $1.45 |
| Resistance Level | $10.75 | $2.14 |
| Average True Range (ATR) | 0.42 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 24.43 | 52.31 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.